GHENT, BELGIUM--(Marketwire - September 27, 2012) - Ablynx (EURONEXT BRUSSELS: ABLX) today
announced that Dr Roger Perlmutter and Dr Russell G. Greig will be
Independent Non-Executive Directors at the Company's forthcoming
General Meeting of its shareholders at the beginning of November 2012.
Dr Edwin Moses, Chairman and CEO of Ablynx, said:
"We are delighted that Roger and Russell are prepared to join the Ablynx
We expect to benefit enormously from their extensive experience in
pharmaceutical companies as well as their numerous interactions
biotechnology companies at all stages of development. We see these
as a very important step in the recognition of Ablynx's unique Nanobody
and in the continuing evolution of Ablynx into a significant player
international biopharmaceutical industry."
Dr Roger Perlmutter
Dr Perlmutter was Executive Vice President, Research and Development, at
Inc, the world's largest biotechnology company, from 2001 to 2012.
joining Amgen, he was the Executive Vice President of Worldwide Basic
and Preclinical Development at Merck and Co. Prior to joining
Perlmutter had been Professor and founding Chairman of the
Immunology at the University of Washington, Seattle, USA.
Dr Perlmutter is currently a Director of StemCells Inc. and the Immune
Corporation. He is also Chairman of the Board of Trustees of Reed College
Director of the Institute for Systems Biology (a not-for-profit
institute based in Seattle, Washington). He is a fellow of the American
of Arts and Sciences, a fellow of the American Association for the
of Science and a past President of the American Association of
Ablynx is the first potential Board mandate that Dr Perlmutter has
outside the USA.
Dr Russell Greig
Dr Greig has more than 30 years' experience in the pharmaceutical industry,
knowledge and expertise in research and development, business
commercial operations. He spent the majority of his career at
where he held a number of positions including GSK's President of
International from 2003 to 2008 and Senior Vice President Worldwide
Development. From 2008 to 2010, Dr Greig was also President of SR One,
Corporate Venture Group. He is currently Chairman of Syntaxin (UK), AM
(The Netherlands) and Isconova (Sweden) as well as a Director of
(Belgium). He also acts as a consultant to Genocea (US), BigDNA
Edinburgh BioQuarter (Scotland), and Kurma Life Sciences (France). He
acting CEO at Genocea and Isconova for an interim period. He is also a
the Scottish Scientific Advisory Committee.
Ablynx is a biopharmaceutical company engaged in the discovery and
of Nanobodies(®), a novel class of therapeutic proteins based on
antibody fragments, for a range of serious human diseases,
inflammation, haematology, oncology and pulmonary disease. Today, the
has approximately 25 programmes in the pipeline and seven Nanobodies at
development stage. Ablynx has ongoing research collaborations and
partnerships with major pharmaceutical companies including Boehringer
Merck KGaA and Novartis. The Company is headquartered in Ghent, Belgium.
information can be found on www.ablynx.com.
press release in pdf:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE